Comparative Pharmacology
Head-to-head clinical analysis: ARISTOCORT A versus CORTRIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARISTOCORT A versus CORTRIL.
ARISTOCORT A vs CORTRIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Triamcinolone acetonide is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, suppress cytokine production, and decrease inflammation and immune responses.
Cortril (hydrocortisone) is a corticosteroid that binds to the glucocorticoid receptor, leading to inhibition of inflammatory mediators and suppression of immune response.
Intralesional injection: 2.5-5 mg per lesion, repeated every 1-2 weeks. Topical: Apply thin film to affected area 2-4 times daily.
Hydrocortisone (Cortril) for adrenal insufficiency: 20-30 mg orally daily divided into two or three doses. For acute conditions, IV or IM hydrocortisone sodium succinate 100 mg every 8 hours.
None Documented
None Documented
Terminal half-life: 2-3 hours for triamcinolone acetonide. Clinical context: Duration of action longer due to receptor binding and intracellular activity; anti-inflammatory effects persist 24-48 hours after IM administration.
Terminal elimination half-life: 1.5–2.5 hours. Clinically, the biologic half-life (duration of ACTH suppression) is longer (8–12 hours).
Renal: 75% as metabolites (primarily conjugated), 15% as unchanged drug. Biliary/fecal: 10%.
Renal (95% as free cortisol and metabolites, primarily tetrahydrocortisol and glucuronide conjugates). Biliary/fecal excretion is minimal (<5%).
Category C
Category C
Corticosteroid
Corticosteroid